Literature DB >> 16226488

Epidemiological aspects of obesity and NASH/NAFLD in Japan.

Nobuo Yoshiike1, Htay Lwin.   

Abstract

Although the characteristics of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) have become well recognized, mainly in the clinical and pathological fields, epidemiological findings, including magnitude of the disease in a population (prevalence, outcomes, and mortality) and risk factors (relative risk and population attributable risk) are scarce in the Asia-Oceania region. Obesity is known to be one of the most important risk factors for NASH/NAFLD, and observed increases in NASH/NAFLD in selected areas or settings may be linked to the increase in overweight and obesity in Japanese adults in the last few decades. Obesity could be a major key to explaining NASH/NAFLD, because of the complex causal web that includes obesity, insulin resistance, dyslipidemia, high blood pressure, etc. In this paper epidemiological data on overweight and obesity were summarized as underlying factors for NAFLD with special reference to yearly trends and regional differences in the prevalence of obesity and overweight in Japanese adults using large-scale representative samples from the National Nutrition Surveys. Unfortunately, as very few published reports on population-based epidemiological data for NAFLD are currently available, we referred to selected data obtained from field settings to estimate the prevalence of NAFLD in the general population and its risk factors or associated factors. It is important to understand NASH/NAFLD as a common "burden of disease" in the populations if effective strategies to control these disorders are to be devised as part of public health initiatives.

Entities:  

Year:  2005        PMID: 16226488     DOI: 10.1016/j.hepres.2005.09.008

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

1.  Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

Authors:  Yuki Kimura; Hideyuki Hyogo; Sho-ichi Yamagishi; Masayoshi Takeuchi; Tomokazu Ishitobi; Yoshitaka Nabeshima; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

Review 2.  Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature.

Authors:  Masafumi Ono; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

3.  The latest idea in NAFLD/NASH pathogenesis.

Authors:  Masafumi Ono; Nobuto Okamoto; Toshiji Saibara
Journal:  Clin J Gastroenterol       Date:  2010-10-26

4.  Etiology of liver cirrhosis in Japan: a nationwide survey.

Authors:  Kojiro Michitaka; Shuhei Nishiguchi; Yutaka Aoyagi; Yoichi Hiasa; Yoshio Tokumoto; Morikazu Onji
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

5.  Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis.

Authors:  Atsushi Kudo; Shinji Tanaka; Daisuke Ban; Satoshi Matsumura; Takumi Irie; Takanori Ochiai; Noriaki Nakamura; Shigeki Arii; Minoru Tanabe
Journal:  J Gastroenterol       Date:  2013-10-18       Impact factor: 7.527

6.  Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis.

Authors:  Kosuke Saito; Takashi Uebanso; Keiko Maekawa; Masaki Ishikawa; Ryo Taguchi; Takao Nammo; Tomoko Nishimaki-Mogami; Haruhide Udagawa; Masato Fujii; Yuichiro Shibazaki; Hiroyuki Yoneyama; Kazuki Yasuda; Yoshiro Saito
Journal:  Sci Rep       Date:  2015-08-20       Impact factor: 4.379

7.  Hepatic adverse effects of fructose consumption independent of overweight/obesity.

Authors:  Alini Schultz; Debora Neil; Marcia B Aguila; Carlos A Mandarim-de-Lacerda
Journal:  Int J Mol Sci       Date:  2013-11-05       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.